To transform developing and least developing countries into industrialised ones,
biotechnology could be deployed along the value chain, to provide support to the …

Highlights•Biologics approvals grew from the early 1980s through 2010, stabilizing
thereafter.•Three different disease categories capture more than 70% of initial antibody …

Therapeutic monoclonal antibodies (mAbs) market is strongly contributing to the rising
growth of the biotechnology industry. Despite the increasing number of inventions over time …

Biopharmaceuticals are one of the most important groups of biotechnological products,
representing one‐quarter of all pharmaceutical sales and providing suitable and efficient …

The biotechnology segment of the overall biopharma industry has existed for only about 40–
45 years, as a driver of new product development. This driving force was initiated with the …

The US legal pathway for biosimilars does not define the weight of evidence required to fulfil
the requirement that an interchangeable biosimilar product 'can be expected to produce the …

Risk Management Plans (RMPs) have become a cornerstone in the pharmacovigilance of
new drugs in Europe. The RMP was introduced in 2005 to support a proactive approach in …

El crecimiento de las empresas en un mundo altamente competitivo depende del
rendimiento superior del proceso de desarrollo de sus productos. En este artículo se …

Biopharmaceuticals are gaining high relevance in the pharmaceutical industry and market,
due to their specific design for many therapeutic conditions and ability to restore biological …

Recently, biotech companies are increasingly attracting the attention from investors. From
2016, of the top 10 performers in the NASDAQ-100 (index consisting of 100 largest non …